Fund moves
232KShares reported
10 tracked managers disclosed the same change for Q4 2024. From a 13F filed Mar 5, 2025 covering holdings at Dec 31, 2024 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Holdings as of Dec 31, 2024 (Q4 2024) · Filed Feb 14, 2025
72 tracked managers disclosed the same change for Q4 2024. From a 13F filed Feb 14, 2025 covering holdings at Dec 31, 2024 — a quarter-end snapshot, not a live trade.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
Increased
Compared with the manager's Q3 2024 13F
837,718
943,058
+12.6%
Share count drives classification; reported value also moves with price
0.37%
Within the filing's reported positions, not the manager's total assets
72
For Q4 2024
Fund moves
10 tracked managers disclosed the same change for Q4 2024. From a 13F filed Mar 5, 2025 covering holdings at Dec 31, 2024 — a quarter-end snapshot, not a live trade.
Insider buying
Traded Feb 20, 2025 · filed 2 days later
The CEO of Bristol Myers Squibb paid $110K out of pocket for Bristol Myers Squibb shares. 1 other person at Bristol Myers Squibb bought some too, in the same month.
Insider buying
Traded Feb 14, 2025 · filed 6 days later
Bristol Myers Squibb's Chief Med.Offr.,Drug Dev. paid $100K out of pocket for Bristol Myers Squibb shares. 1 other person at Bristol Myers Squibb bought some too, in the same month.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.